Journal of Liver: Disease & TransplantationISSN: 2325-9612

Reach Us +1 850 900 2634
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, J Liver Dis Transplant Vol: 5 Issue: 1

Analysis of Pretreatment Predictors of a Virological Response to Interferon Therapy in Co-infected Patients of Hepatitis C and B

Maleha Asim1*, Amir Rashid2, Asifa Majeed2 and Suhail Razak2
1Department of Biochemistry, Foundation University Medical College, Islamabad, Pakistan
2Department of Biochemistry and Molecular Biology, Army Medical College, National University of Sciences and Technology, Rawalpindi, Pakistan
Corresponding author : Maleha Asim
Department of Biochemistry, University Medical College, Islamabad, Pakistan
Tel/Fax: 0092-051-9273583
E-mail: [email protected]
Received: November 09, 2015 Accepted: March 10, 2016 Published: March 16, 2016
Citation: Asim M, Rashid A, Majeed A, Razak S (2016) Analysis of Pretreatment Predictors of a Virological Response to Interferon Therapy in Co-infected Patients of Hepatitis C and B. J Liver: Dis Transplant 5:1. doi:10.4172/2325-9612.1000134

Abstract

Background: Several pretreatment parameters are strongly associated with sustained virological response rate (SVR) in HCV/ HBV co-infected patients.

Methods: We identified 104 HCV/HBV co-infected patients (69 males and 35 females) who were treated with standard interferon-alfa-2a or pegylated-IFN-alfa-2b by using electronic query. Data analysis includes their age, gender, clinical, hierological and histological parameters.Patients were divided into two groups of interferon responders (negative HCV RNA level) and non-responders (patients with positive HCV-RNA levels). Multivariate regression analysis was used to assess the effect of pre-treatment variables and therapy regime on sustained virological rate (SVR) in both groups.

Results: The pretreatment parameters significantly associated with sustained virological response to interferon therapy were low levels of serum ALT (p=0.002), HCV-RNA (?4×105 IU/ml) (p=0.038), HBVDNA(?2×104 IU/ml) (p=0.002), HCV genotype-3 (p=0.025) and IL- 28B CC genotype (p=0.049). As for histological factors, normal to minimal change in liver biopsy was found considerably associated with therapy response (p=0.024). Significant advantage of peginterferon plus ribavirin was also observed for SVR (p=0.004).Post-treatment HBV-DNA clearance was observed in 22% of 104 co-infected patients.

Conclusion: Pretreatment parameters are closely related with better response to therapy. Peg-interferon and ribavirin in combination is an effective regime significantly associated with SVR in HCV/HBV co-infected patients.

 

Keywords: Co-infection; Hepatitis B; Hepatitis C; Interferon therapy; Pretreatment parameters; Sustained virological response

Track Your Manuscript

Share This Page